Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.
作者信息
Bumm Thomas, Deininger Jutta, Newell Amy Hanlon, Lawce Helen, Olson Susan, Mauro Michael, Druker Brian, Deininger Michael
机构信息
Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA.
Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
出版信息
Leukemia. 2010 Aug;24(8):1525-1528. doi: 10.1038/leu.2010.123. Epub 2010 Jun 10.
Abstract
摘要
相似文献
1
Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.来自细胞遗传学正常的慢性髓性白血病患者、对酪氨酸激酶抑制剂有完全细胞遗传学反应的CD34+/CD38-造血细胞中的克隆性染色体异常。
Leukemia. 2010 Aug;24(8):1525-1528. doi: 10.1038/leu.2010.123. Epub 2010 Jun 10.
2
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.附加染色体异常和 BCR-ABL 激酶结构域突变对费城染色体阳性慢性髓性白血病患者接受尼罗替尼治疗反应的影响。
Haematologica. 2010 Apr;95(4):582-8. doi: 10.3324/haematol.2009.014712. Epub 2009 Dec 16.
3
CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome.CD34+/CD38- 干细胞负担可预测慢性髓性白血病患者的结局。
Asian Pac J Cancer Prev. 2021 Oct 1;22(10):3237-3243. doi: 10.31557/APJCP.2021.22.10.3237.
4
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.甲磺酸伊马替尼治疗后完全细胞遗传学缓解的慢性髓性白血病患者中恶性造血祖细胞的持续存在。
Blood. 2003 Jun 15;101(12):4701-7. doi: 10.1182/blood-2002-09-2780. Epub 2003 Feb 6.
5
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗时代慢性髓性白血病髓系与淋系原始细胞期额外染色体异常的差异影响
Leukemia. 2016 Jul;30(7):1606-9. doi: 10.1038/leu.2016.6. Epub 2016 Feb 3.
6
Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.在接受酪氨酸激酶抑制剂治疗后处于完全细胞遗传学缓解期的慢性髓性白血病患者中，费城染色体阳性白血病干细胞（Ph(+)CD34(+)CD38(neg)）数量低或检测不到
Leukemia. 2010 Jan;24(1):219-22. doi: 10.1038/leu.2009.190. Epub 2009 Sep 24.
7
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.评价一线尼洛替尼治疗后达到完全细胞遗传学缓解的慢性髓性白血病患者体内残留的 CD34(+) Ph(+)祖细胞。
Cancer. 2012 Nov 1;118(21):5265-9. doi: 10.1002/cncr.27506. Epub 2012 Apr 19.
8
9
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34CD38 stem and progenitor cells in chronic myeloid leukemia.在慢性髓性白血病中，通过5-脂氧合酶（ALOX5）和半胱氨酰白三烯受体1的白三烯信号传导对于CD34⁺CD38⁻干细胞和祖细胞的体外生长并非必需。
Biochem Biophys Res Commun. 2017 Aug 19;490(2):378-384. doi: 10.1016/j.bbrc.2017.06.051. Epub 2017 Jun 13.
10
Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors.慢性粒细胞白血病患者经酪氨酸激酶抑制剂治疗后费城阴性细胞中克隆性染色体异常的临床意义
Cancer Genet. 2019 Oct;238:44-49. doi: 10.1016/j.cancergen.2019.07.008. Epub 2019 Jul 24.
引用本文的文献
1
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.PP2A 激活剂药物选择性根除 TKI 耐药性慢性髓性白血病干细胞。
J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.
2
Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion.JAK2V617F 降低了单个造血干细胞的自我更新能力，而不影响祖细胞的扩增。
PLoS Biol. 2013;11(6):e1001576. doi: 10.1371/journal.pbio.1001576. Epub 2013 Jun 4.
3
Cancer stem cells: an evolving concept.癌症干细胞：一个不断发展的概念。
Nat Rev Cancer. 2012 Jan 12;12(2):133-43. doi: 10.1038/nrc3184.
本文引用的文献
1
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.费城染色体阴性细胞中存在克隆性细胞遗传学异常的慢性髓性白血病患者的预后。
Cancer. 2007 Oct 1;110(7):1509-19. doi: 10.1002/cncr.22936.
2
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.在新诊断的慢性期慢性髓性白血病患者甲磺酸伊马替尼治疗期间出现的费城染色体阴性中期的染色体异常。
Blood. 2007 Oct 15;110(8):2991-5. doi: 10.1182/blood-2007-01-070045. Epub 2007 Jul 11.
3
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.在转化的JAK2-V617F阳性骨髓增殖性疾病中，白血病原始细胞的JAK2-V617F突变常常呈阴性。
Blood. 2007 Jul 1;110(1):375-9. doi: 10.1182/blood-2006-12-062125. Epub 2007 Mar 15.
4
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.慢性粒细胞白血病接受甲磺酸伊马替尼治疗后发生的骨髓增生异常综合征和急性白血病。
Blood. 2006 Oct 15;108(8):2811-3. doi: 10.1182/blood-2006-04-017400. Epub 2006 Jun 29.
5
Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib.
Leuk Lymphoma. 2004 Nov;45(11):2197-203. doi: 10.1080/10428190410001723278.
6
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.在一些接受伊马替尼治疗后处于细胞遗传学缓解期的慢性粒细胞白血病患者中，Ph-细胞出现克隆性细胞遗传学异常，但大多数患者恢复了多克隆造血。
Blood. 2003 Mar 1;101(5):1941-9. doi: 10.1182/blood-2002-07-2053. Epub 2002 Oct 31.
7
Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations.干细胞和祖细胞：起源、表型、谱系定向及转分化
Annu Rev Cell Dev Biol. 2001;17:387-403. doi: 10.1146/annurev.cellbio.17.1.387.
8
Evidence for a multistep pathogenesis of chronic myelogenous leukemia.慢性粒细胞白血病多步骤发病机制的证据。
Blood. 1981 Jul;58(1):158-63.
9
Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia.慢性粒细胞白血病干扰素诱导细胞遗传学缓解中的多克隆造血
Blood. 1992 Feb 15;79(4):997-1002.
Zotero 插件